AOD-9604
Lipolytic FragmentHover to zoom

Qualified Research Reference

AOD-9604

AOD-9604 is documented for controlled research models and literature-based evaluation only.

Lab TestedThird-party · Janoshik Analytical · ISO 17025View COA / Lab Report →
Formulation Strength
10mgper vial
Member Pricing
Regular
$99.99
Elite Member10%
$89.99
1
Research Description

AOD-9604 is a modified fragment of the C-terminus of human growth hormone (residues 176–191), supplied as a lyophilized peptide. Produced for laboratory research only.

Investigated in adipose metabolism, lipolytic pathway modeling, and fragment-specific growth hormone research.

Research Use Only. This product is intended exclusively for laboratory research and is not approved for human or veterinary use.

Research Profile

AOD-9604: investigational profile.

Research Mechanism

A modified fragment of the C-terminus of human growth hormone (residues 176–191) investigated for lipolytic pathway activity independent of full-length GH signaling.

Investigational Profile

Fragment research on this sequence has appeared in the adipose-metabolism literature since the 1990s and is a standard reference in fragment-versus-holohormone comparisons.

Research Study Window

Adipocyte and lipolysis endpoints are usually captured across two- to six-week laboratory observation periods in preclinical protocols.

Pairs With

MOTS-c

Pairs With

MOTS-c

Formulation

Ingredients, disclosed.

Every compound and formulation strength documented without proprietary blends.

Compound
Dose
Research Context
AOD-9604
Per protocol
Modified C-terminal fragment of human growth hormone (residues 176–191), supplied for lipolytic-pathway research.
Characteristics

Composition, documented.

Molecular Formula
C78H123N23O23S2
Molar Mass
1815.1 g/mol
Amino Acid Sequence
H-Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH
Synonyms
Growth Hormone Fragment 176-191, hGH 176-191
Solubility
Water-soluble
Organoleptic Profile
White to off-white powder
Composition
Lyophilized powder
FAQ

Questions, answered.